Wave Life Sciences Ltd. filings document a clinical-stage biotechnology company developing RNA medicines through the PRISM platform and Nasdaq-listed $0 par value ordinary shares under WVE. Its 8-K reports furnish operating and financial results, Regulation FD corporate presentations and material-event disclosures tied to clinical programs, regulatory communications and pipeline updates for oligonucleotide candidates including WVE-006 and WVE-007.
Proxy and governance filings cover shareholder voting matters, board and governance disclosures, material agreements, capital-structure information and risk factors. The company's formal disclosures also address clinical and regulatory risks, collaboration-related matters, financial condition, and the corporate controls associated with an RNA-medicines development business.
Wave Life Sciences, Inc. common shares were reported as beneficially owned by BlackRock, Inc. in an amount of 13,356,138 shares, or 6.8% of the class. BlackRock reported sole voting power over 13,040,746 shares and sole dispositive power over 13,356,138 shares; shared voting and dispositive power were both zero.
The report states that various persons had rights to dividends or sale proceeds, but no one person's interest in the common stock was more than 5% of the outstanding common shares.
Wave Life Sciences, Inc. (WVE) is the issuer for which BlackRock, Inc. reports beneficial ownership of 0 shares of common stock, or 0.0%, with zero sole or shared voting and dispositive power. The report covers certain BlackRock business units and excludes securities, if any, held by other business units whose ownership is disaggregated from those reporting units. BlackRock states that no one person’s interest exceeds 5% of Wave’s total outstanding common shares.
Wave Life Sciences, Inc. (WVE) reported third-quarter 2026 revenue of $13.158 million, compared with $7.608 million a year earlier, while net loss was $61.912 million versus $53.852 million. Revenue was recognized under the GSK collaboration agreement; the quarter included a $12.0 million milestone after GSK selected a candidate for its development pipeline.
As of September 30, cash, cash equivalents and marketable securities totaled $431.0 million; operating cash use for the first nine months was $173.277 million versus $153.717 million a year earlier. Management expects these resources to fund operations for at least the next 12 months from the financial statements’ issuance date. Interim WVE-007 obesity-trial data included a 14% placebo-adjusted reduction in visceral fat at six months after a single 240 mg dose. Planning is underway for a two-year WVE-006 registrational trial, with a one-year interim analysis to support potential accelerated approval based on AATD biomarkers. Wave expects additional WVE-007 and WVE-006 data and to file a WVE-008 clinical trial application in Q4 2026.
Wave Life Sciences, Inc. reported third-quarter 2026 revenue of $13.158 million, compared with $7.608 million in the third quarter of 2025, and a net loss of $61.912 million, versus $53.852 million. It reported $431.0 million in cash, cash equivalents and marketable securities as of September 30, 2026; an additional $12 million milestone from GSK is expected in the fourth quarter of 2026, and Wave expects cash runway into the third quarter of 2028.
Following positive FDA feedback, planning is underway for a potentially registrational WVE-006 trial in AATD, with an interim analysis for potential accelerated approval based on biomarkers. WVE-007 dosing continues in a Phase 2a monotherapy trial for individuals with higher BMI and comorbidities; its Phase 2a combination trial is underway, and a post-incretin maintenance trial remains on track to start in the fourth quarter of 2026. A CTA submission for WVE-008 is on track for the fourth quarter of 2026. GSK selected a GalNAc-siRNA development candidate using Wave’s SpiNA design, while three additional collaboration programs advance toward potential candidate selection.
Wave Life Sciences, Inc. asks stockholders to vote at its November 12, 2026 annual meeting on four proposals: elect nine directors, ratify KPMG LLP as auditor for fiscal 2026, approve an amendment increasing shares available under the 2021 Equity Incentive Plan, and cast a non-binding advisory vote on named executive officer compensation. The board recommends approval of each proposal.
The meeting was postponed from its historical August schedule following the completed redomiciliation on August 7, 2026, which made Wave Life Sciences, Inc. the ultimate parent and Wave Life Sciences Ltd. its indirect wholly owned subsidiary. The record date was October 8, 2026, when 197,228,058 common shares were issued and outstanding. At the 2025 annual meeting, over 99% of votes cast supported the advisory compensation proposal; the compensation committee said no significant program changes were necessary at that time.
Wave Life Sciences, Inc. (WVE) reported director Peter Kolchinsky’s October 5, 2026 grant of 10,700 restricted stock units and an option award covering 64,000 ordinary shares. The options have a $3.75 per-share exercise price and expire October 5, 2036. Both awards vest 100% on the earlier of the issuer’s 2027 annual meeting of stockholders or October 5, 2027. Kolchinsky holds the awards for the benefit of RA Capital Healthcare Fund, L.P. under an arrangement with RA Capital Management, L.P.
Wave Life Sciences, Inc. director Gregory L. Verdine received a 10,700-share restricted stock unit award and an option covering 64,000 shares on October 5, 2026. The option has a $3.75 exercise price and expires October 5, 2036. Direct common-stock holdings following the RSU award were 200,917 shares. A separate indirect holding lists 75,000 common shares held in a trust by Lynet Holdings LLC. Verdine is the LLC’s sole manager and the trust’s settlor, may be deemed to share voting and investment power over those shares, and disclaims beneficial ownership except to the extent of his pecuniary interest.
Wave Life Sciences, Inc. director Aik Na Tan received a 10,700-share restricted stock unit award and options covering 64,000 common shares on October 5, 2026, under the 2026 Non-Employee Director Compensation Policy. The options have a $3.75 exercise price and expire October 5, 2036. Both awards vest 100% on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. Following the awards, Tan held 35,668 common shares directly and 64,000 options.
Wave Life Sciences, Inc. (WVE) director Ken Takanashi received a 10,700-share restricted stock unit award and an option award covering 64,000 shares on October 5, 2026. Both awards vest 100% on the earlier of the company’s 2027 annual meeting of stockholders or October 5, 2027. After the RSU award, Takanashi directly held 30,779 common shares. SNBL USA, Ltd. and Shin Nippon Biomedical Laboratories, Ltd. were reported as holding shares indirectly; Takanashi disclaimed beneficial ownership except to the extent of his pecuniary interest.